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Abstract: Based on promising preclinical efficacy of bortezomib 
in mesothelioma, a single-arm phase II trial (Ireland Cooperative 
Oncology Research Group 05-10 study), with Simon’s two-stage 
design, was undertaken to assess efficacy of bortezomib monotherapy 
in the first-line (poor performance status) and second-line settings. 
The Bcl-2 homology domain 3-only protein Noxa has been impli-
cated as a key inducer of apoptosis by bortezomib. Thus, in a bio-
marker research substudy, we hypothesized that deficiency in Noxa 
expression might correlate with resistance. In the second-line set-
ting, 23 patients were enrolled. Partial response was confirmed in one 
patient (4.8%) who received four cycles of bortezomib. One patient 
had stable disease; however, progression occurred in the majority of 
patients within the first two cycles. Median progression-free survival 
and overall survival were 2.1 and 5.8 months, respectively. In the 
first-line setting, ten patients were accrued, and there was no evidence 
of objective response. In the tumor analysis, expression of Noxa was 
seen in all biopsies. Bortezomib monotherapy exhibits insufficient 
activity to warrant further investigation in unselected patients with 
mesothelioma.
Key Words: Mesothelioma, Bortezomib, Chemotherapy, First-line, 
Second-line.
(J Thorac Oncol. 2012;7: 1466–1470)
The incidence of malignant pleural mesothelioma (MPM) is increasing in Europe and this trend is set to continue 
over the next decade.1 The majority of patients present with 
advanced disease for which systemic therapy is the standard 
of care.2 Pemetrexed-cisplatin is the standard treatment for 
patients in the first-line setting.3 However, there is currently 
no approved standard of care for patients who have relapsed. 
Several trials have failed to show useful activities in the sec-
ond-line setting.4,5
Bortezomib is an inhibitor of the 20s proteasome and is 
licenced for the treatment of myeloma. Bortezomib activates 
the intrinsic apoptotic pathway by transcriptionally up-reg-
ulating the proapoptotic B-cell lymphoma 2 family proteins 
Noxa, p53 upregulated modulator of apoptosis, and bcl-2 
interacting mediator of cell death (BIM).6
In preclinical models of mesothelioma, bortezomib has 
demonstrated promising activity, warranting its therapeutic 
evaluation.7,8 Accordingly, the Ireland Cooperative Oncology 
Research Group 05-10 clinical trial was designed to evalu-
ate the efficacy of bortezomib monotherapy in the second-line 
patients and in patients who were unfit to or were unwilling to 
receive first-line platinum-based chemotherapy.
PATIENTS AND METHODS
Inclusion Criteria
Patients were considered eligible if they had histologi-
cal evidence of MPM, performance status of 0 to 2 by Eastern 
Cooperative Group (ECOG) criteria, adequate hematological 
status (hemoglobin ≥10 g/dL; neutrophil count ≥1.5 × 109/
liter; and platelets ≥ 100 × 109/liter), adequate hepatic function 
(aspartate transaminase and alanine transaminase <3 × upper 
limit of normal), adequate renal function (creatinine clearance 
≥50 ml/min determined by Cockcroft–Gault method). There 
was a requirement where possible for pleural effusions to be 
drained before treatment and for uncontrolled pleural effusions 
to be managed as per standard practice by talc or tetracycline 
pleurodesis. For patients in the chemo-naive treatment setting, 
they had to be either unsuitable for or not willing to receive 
combination chemotherapy. All patients provided consent 
to participate in this study, which was conducted according 
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to the International Conference on Harmonisation—Good 
Clinical Practice standards. Baseline evaluation included rou-
tine hematology and biochemistry, which were required on 
the first day of each treatment cycle. Computed tomography 
(CT) scan of the involved areas (chest, plus abdomen, or 
pelvis) was conducted a maximum of 28 days before com-
mencing bortezomib. Repeat CT scans were conducted after 
every two treatment cycles. Responding patients had a further 
confirmatory CT scan at 1 month.
Treatment Schedule
Patients received bortezomib at 1.6 mg/m2 administered 
weekly on days 1, 8, 15, and 22 of a 35-day (5-week) cycle. 
This schedule was determined as the maximum tolerated 
dose reported for patients with androgen-resistant prostate 
cancer, treated in a phase 1 trial.9 Treatment was continued 
until disease progression in those patients exhibiting objective 
responses or stable disease by 20 weeks.
Dose Modification
Dose adjustments were made for common toxicity cri-
teria grade 3 or 4 toxicities. Only two dose reductions were 
permitted, after which treatment was discontinued.
Noxa Immunohistochemistry
Immunohistochemistry was performed on 18 paraffin-
embedded primary mesothelioma tissues. The staining was 
carried out, as previously described,10 with a 1:200 dilution 
of a monoclonal antibody against Noxa (OP180; Oncogene 
Science, San Diego, CA) for 2 hours. Isotype immunoglobin 
G1 was used as negative control. The Noxa immunohisto-
chemistry scoring of tissue microarray slides was carried 
out using the PathXLTMA Toolbox (i-Path Diagnostics Ltd, 
Belfast, United Kingdom). Through this application, the lung 
pathologist could remotely access high resolution slide scans 
and perform scoring. Noxa-positive tumors were defined as 
those demonstrating 10% or more cells with staining.
Statistical Analysis
The primary end point was response rate measured by 
modified Response Evaluation Criteria In Solid Tumors crite-
ria.11 Secondary end points were time to progression and over-
all survival. A two-stage optimal Simon’s design based on the 
observed tumor response was employed. Second-line hypothe-
sis tested: p0 ≤ 0.05 and p1 ≥ 0.17 (α = 0.05, β = 0.1) requiring 
n = 23 patients and 2 responders to continue to N=70 in total. 
First-line: p0 ≤ 0.1, p1 ≥ 0.25 (α = 0.05, β = 0.1), stage one 
sample N = 21, requiring 3 responders to continue to N = 66.
RESULTS
First-Line Activity in Patients With 
Poor Performance Status
In the first-line setting, 10 patients were enrolled 
between July 19, 2006 and October 29, 2009, of whom nine 
were eligible for response and toxicity assessment. Because of 
slow accrual, enrollment was discontinued prematurely. The 
patient characteristics are summarized in Table 1. The major-
ity of patients were men, with a median age of 67.9 (range, 
59–81), epithelioid histology, and ECOG performance status 
of 0 to 1 in 80%. Patients received a median of three treatment 
cycles (range, 1–4) with a total of 28 cycles administered to 
10 patients; 10 patients (100%) completed cycle 1, 8 patients 
(89%) completed cycle 2, 5 patients (50%) completed cycle 3, 
and 3 patients (30%) completed cycle 4.
No patient received more than 4 cycles of bortezo-
mib. Grade 3 or 4 toxicities associated with bortezomib are 
shown in Table 2. Dose reductions occurred in no patient. 
Discontinuation because of adverse reactions occurred in one 
patient attributable to grade 2 toxicity (atrial fibrillation and 
congestive heart failure), after study withdrawal but within 30 
days of last treatment.
In the efficacy population, no patient had a partial 
response, and one patient (11 %) had stable disease during 
four cycles of treatment. Progressive disease in the first two 
cycles occurred in 5 patients (56%), and 5 patients (56%) 
progressed before cycle 4. There were 2 deaths (22%) before 
completion of four cycles of therapy, both of which occurred 
TABLE 1.  Summary of Patient Characteristics (First-Line and 
Second-Line Bortezomib)
 
Characteristic
First-Line Second-Line
N=10 N=23
Sex
 Men 8 (80%) 20 (87%)
 Women 2 (20%) 3 (13%)
Age
 Median 67 65
 ≥70 4 (40%) 6 (26%)
Histology
 Epithelioid 3 (30%) 16 (70%)
 Sarcamatoid 1 (10%) 2 (9%)
 Mixed (biphasic) 1 (10%) 1 (4%)1 (4%)
 Subtype, unknown 5 (50%) 3 (13%)
ECOG performance status
 0 3 (30%) 5(2
 1 5 (50%) 17 (74%)
 2 2 (20%) 0 (0%)1 (4%)
White cell count at baseline
 Mean (SD) 9.6 (2.47) 9.0 (3.55)
ECOG, Eastern Cooperative Oncology Group.
TABLE 2. Patient Counts of Adverse Events By Maximum 
Toxicity by Treatment Line n (%)
CTC Grade  
Total1 2 3 4
First line 1 (10%) 5 (50%) 4 (40%) 0 (0%) 10 (100%)
Second line 2 (8.7%) 11 (47.8%) 6 (26.1%) 4 (17.4%) 23 (100%)
CTC, common toxicity criteria.
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after study withdrawal and within 30 days of last treatment. 
Median time to progression was 2.23 months, Figure 1A, and 
median overall survival was 10.55 months, Figure 1B.
Second-Line Bortezomib
In the second-line setting, 23 patients were enrolled 
between May 23, 2006 and October 18, 2007 and 21 were 
eligible for response and toxicity. The patient characteristics 
are summarized in Table 1. The majority of patients were men, 
with a median age of 64.7 (range, 49–78), 65% of patients had 
epithelioid histology and ECOG performance status of 0 to 
1 (96%). Patients received a median of two treatment cycles 
(range, 1–4), and a total of 49 cycles were administered to 23 
patients. No patient received more than four cycles of bortezo-
mib; 21 patients (91%) completed cycle 1, 17 patients (74%) 
completed cycle 2, 3 patients (13%) completed cycle 3, and 2 
patients (9%) completed cycle 4. Grade 3 or 4 toxicities asso-
ciated with bortezomib are shown in Table 2. Dose reductions 
occurred for 3 patients because of grade 3 anemia, fatigue, and 
peripheral sensory neuropathy, respectively. Discontinuation 
because of adverse toxicities occurred in 1 patient attributable 
to a grade 4 event (fecal impaction).
One patient (4.8% of efficacy population) had a partial 
response, which was confirmed and associated with reduction 
in the size of an invasive chest-wall mass. The responder was a 
man with epithelioid histology, who had received carboplatin 
and pemetrexed in the first-line setting with stable disease as 
best overall response. This patient went on to receive a total 
of four cycles of bortezomib (cycles 2–4 at a reduced dose 
of 1.3 mg/m2). This patient relapsed in the sixth month of 
follow-up, and died in the 22nd month of follow-up. In the 
FIGURE 1. A, Kaplan–Meier for disease progression—first line patients, median time to progression was 2.23 months (95% 
confidence limits 1.15–4.76). B, Kaplan–Meier for overall survival—first line patients. Median overall survival was 10.55 months 
(95% confidence limits 1.77–not applicable). C, Kaplan–Meier for disease progression—second line patients. Median time to 
progression was 2.1 months (95% confidence limits 1.84–2.07). D, Kaplan–Meier for overall survival—second line patients. 
Median overall survival was 5.78 months (95% confidence limits 3.12–9.43).
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efficacy population, 1 patient (4.8%) had stable disease for 
one to four cycles. Progressive disease occurred in the first 
two cycles in 86% of the patients, and 19 patients (90%) had 
progressed before cycle four. There were 7 deaths (33%) 
before completion of four cycles of therapy, five of which 
(23.8%) occurred after study withdrawal and within 30 days 
of last treatment. Median time to progression was 2.1 months, 
Figure 1C, and median overall survival was 5.78 months, 
Figure 1D. On the basis of the observed response rate in the 
first stage of the study, the null hypothesis was accepted, and it 
was decided to discontinue accrual.
Expression of the BH3-Only Protein Noxa
Preclinical data has demonstrated that lack of Noxa 
expression leads to a significant attenuation of bortezomib 
toxicity.12 We therefore hypothesised that constitutive defi-
ciency in Noxa expression might correlate with resistance 
to bortezomib. By using a predefined threshold of less than 
10% of Noxa expression for defining immunonegativity, we 
conducted pathological review of 18 archival mesothelioma 
specimens. No immunonegative samples were found as Noxa 
was expressed in all samples from patients receiving bortezo-
mib, Figure 2.
DISCUSSION
Based on promising in vivo preclinical data, we under-
took a multicenter phase II trial in the first- and second-line 
setting. Single agent efficacy was insufficient in the first stage 
to justify enrollment into the second stage. Enrolment was 
also confounded by difficulty in identifying sufficient patients 
with an ECOG Performance Status of 2 who were suitable 
for enrollment, most patients being sufficiently fit to receive 
standard treatment.
There have been few reported clinical trials in the 
second-line treatment setting in MPM, mainly single-arm, 
nonrandomized studies. To date there has been only one 
large randomized phase III trial, in which patients received 
pemetrexed or best supportive care. Although activity 
(progression-free survival increase) was evident in the 
experimental arm, there was no significant impact on overall 
survival.13 At present there is no standard of care for patients 
with MPM who have progressed after pemetrexed-cisplatin. 
We considered bortezomib to be a promising drug because of 
its effects in preclinical mesothelioma models.7,8 The protein 
Noxa has been implicated in mediating the proapoptotic 
effects of bortezomib in several cancers6,14 and was suggested 
as a preclinical biomarker for responsiveness to bortezomib 
treatment in vitro and in vivo. However, it was demonstrated 
that the induction of Noxa is necessary but not sufficient for 
bortezomib-induced apoptosis in neuroblastoma cells; indeed 
Noxa can act as sensitzser but does not induce death per 
se.15 Here, we show that Noxa is equally expressed in all the 
analyzed samples irrespective of the response to bortezomib 
treatment, disproving its role as a biomarker in mesothelioma. 
In summary, bortezomib as a monotherapy exhibits insufficient 
activity to warrant its further investigation in unselected 
patients with MPM.
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